Table 3.

New compounds for VTE identified from recent clinical trials.

Conditions	Compounds	Mechanism of Action	Phase	Sponsor	Ref.
Pulmonary embolism; thrombotic disease	DS-1040b	Inhibits the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa).	Phase 1|Phase 2	Daiichi Sankyo	[115,116]
VTE prophylaxis with anticoagulation after total knee replacement surgery	JNJ-64179375	Specific exosite 1 thrombin inhibitor	Phase 2	Janssen Research & Development, LLC Tetherex	[117,118]
VTE	SelK2	Targets PSGL-1 and blocks its interactions	Phase 2	Pharmaceuticals Corporation	[119]
Thromboembolism of vein VTE in colorectal cancer, pancreatic cancer, non-small cell lung cancer	Isoquercetin	Decreases D-dimer, P-selectin, and platelet-dependent fibrin generation	Phase 2|Phase 3	Quercegen Pharmaceutical; National Heart, Lung, and Blood Institute (NHLBI)	[120]